J&J’s Janssen taps into Pipeline Therapeutics’ neuroscience asset for $50M upfront
2023-04-17
临床1期蛋白降解靶向嵌合体
Johnson & Johnson’s Janssen unit is delving into the muscarinic space with $50 million upfront for an oral Pipeline Therapeutics asset that will enter a Phase II in the second half of this year, CEO and president Carmine Stengone told
Endpoints News
.
The San Diego biotech tested its investigational compound, the muscarinic M1 antagonist PIPE-307, in
two
Phase I
studies
and has gained an FDA go-ahead for a mid-stage study in patients with relapsing-remitting multiple sclerosis, or RRMS. After the Phase I studies showed a “clean
safety profile
,” Pipeline attracted “a fair bit of partnering interest,” with a few term sheets negotiated during the process, Stengone said.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。